{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:13:20Z","timestamp":1788812000491,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"DOI":"10.1007\/s11845-026-04591-w","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:01:06Z","timestamp":1788768066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and hematological parameters associated with omalizumab response in chronic spontaneous urticaria"],"prefix":"10.1007","author":[{"given":"Hacer","family":"Vural Karatoprak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serpil","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9076-4669","authenticated-orcid":false,"given":"Dursun","family":"Turkmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Enes","family":"G\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihal","family":"Altunisik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekiye","family":"Kanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba","family":"Vural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"4591_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00627","author":"SJ Bracken","year":"2019","unstructured":"Bracken SJ, Abraham S, MacLeod AS (2019) Autoimmune theories of chronic spontaneous urticaria. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.00627","journal-title":"Front Immunol"},{"issue":"12","key":"4591_CR2","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1111\/1346-8138.17943","volume":"52","author":"A Fukunaga","year":"2025","unstructured":"Fukunaga A, Kishi Y, Sunaga Y, Arima K (2025) Prevalence, Comorbidities, and Current Management of Chronic Spontaneous Urticaria in Japan: Retrospective Claims Database Study. J Dermatol 52(12):1775\u20131787. https:\/\/doi.org\/10.1111\/1346-8138.17943","journal-title":"J Dermatol"},{"issue":"7","key":"4591_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","volume":"161","author":"A Gim\u00e9nez-Arnau","year":"2025","unstructured":"Gim\u00e9nez-Arnau A, Ferrucci S, Ben-Shoshan M et al (2025) Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial. JAMA Dermatol 161(7):679\u2013687. https:\/\/doi.org\/10.1001\/jamadermatol.2025.0733","journal-title":"JAMA Dermatol"},{"issue":"2","key":"4591_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000445058","volume":"169","author":"B Frossi","year":"2016","unstructured":"Frossi B, De Carli S, Bossi F, Pucillo C, De Carli M (2016) Co-Occurrence of Chronic Spontaneous Urticaria with Immunoglobulin A Deficiency and Autoimmune Diseases. Int Arch Allergy Immunol 169(2):130\u2013134. https:\/\/doi.org\/10.1159\/000445058","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"4591_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M et al (2022) The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 77(3):734\u2013766. https:\/\/doi.org\/10.1111\/all.15090","journal-title":"Allergy"},{"issue":"4","key":"4591_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15586\/aei.v53i4.1343","volume":"53","author":"\u00d6\u00d6 Akta\u015f","year":"2025","unstructured":"Akta\u015f \u00d6\u00d6, \u00c7im\u015fir D\u00d6, B\u00fclb\u00fcl EN et al (2025) Biomarkers of response to omalizumab in patients with chronic spontaneous urticaria. Allergol Immunopathol (Madr) 53(4):7\u201313. https:\/\/doi.org\/10.15586\/aei.v53i4.1343","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"4","key":"4591_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/all.13083","volume":"72","author":"AP Kaplan","year":"2017","unstructured":"Kaplan AP, Gim\u00e9nez-Arnau AM, Saini SS (2017) Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 72(4):519\u2013533. https:\/\/doi.org\/10.1111\/all.13083","journal-title":"Allergy"},{"issue":"1","key":"4591_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-018-0255-8","volume":"14","author":"R Grzanka","year":"2018","unstructured":"Grzanka R, Damasiewicz-Bodzek A, Kasperska-Zajac A (2018) Interplay between acute phase response and coagulation\/fibrinolysis in chronic spontaneous urticaria. Allergy Asthma Clin Immunol 14(1):27. https:\/\/doi.org\/10.1186\/s13223-018-0255-8","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"4591_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/15569527.2018.1495227","volume":"38","author":"E Acer","year":"2019","unstructured":"Acer E, Kaya Erdogan H, Y\u00fcksel \u00c7anak\u00e7\u0131 N, Saracoglu ZN (2019) The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria. Cutan Ocul Toxicol 38(1):5\u20138. https:\/\/doi.org\/10.1080\/15569527.2018.1495227","journal-title":"Cutan Ocul Toxicol"},{"issue":"1","key":"4591_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.23822\/EurAnnACI.1764-1489.272","volume":"56","author":"D Baskurt","year":"2024","unstructured":"Baskurt D, Sarac E, Asero R, Kocat\u00fcrk E (2024) D-dimer levels decline after immunosuppressive treatment rather than anticoagulant treatment in severe autoimmune chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol 56(1):42\u201344. https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.272","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"4591_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072639","author":"B Tarkowski","year":"2023","unstructured":"Tarkowski B, \u0141awniczak J, Tomaszewska K, Kurowski M, Zalewska-Janowska A (2023) Chronic urticaria treatment with omalizumab\u2014verification of NLR, PLR, SIRI and SII as biomarkers and predictors of treatment efficacy. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12072639","journal-title":"J Clin Med"},{"issue":"8","key":"4591_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15589","volume":"35","author":"NC Co\u015fansu","year":"2022","unstructured":"Co\u015fansu NC, Kara R\u00d6, Yaldiz M, Dikicier BS (2022) New markers to predict the response to omalizumab in chronic spontaneous urticaria. Dermatol Ther 35(8):e15589. https:\/\/doi.org\/10.1111\/dth.15589","journal-title":"Dermatol Ther"},{"issue":"4","key":"4591_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.5114\/pja.2025.156073","volume":"12","author":"\u00d6 Atik","year":"2025","unstructured":"Atik \u00d6, Can A (2025) Evaluation of the relationship between multiple inflammatory markers, disease severity and antihistamine response in chronic spontaneous urticaria. Alergol Pol 12(4):286\u2013291. https:\/\/doi.org\/10.5114\/pja.2025.156073","journal-title":"Alergol Pol"},{"issue":"06","key":"4591_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.23822\/EurAnnACI.1764-1489.307","volume":"55","author":"R Asero","year":"2023","unstructured":"Asero R, Tedeschi A (2023) Chronic spontaneous urticaria: from the hunt for causes and pathogenesis to the identification of different endotypes. Eur Ann Allergy Clin Immunol 55(06):253. https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.307","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"4","key":"4591_CR15","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jaip.2017.10.030","volume":"6","author":"MD Straesser","year":"2018","unstructured":"Straesser MD, Oliver E, Palacios T et al (2018) Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract 6(4):1386\u20131388e1. https:\/\/doi.org\/10.1016\/j.jaip.2017.10.030","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4591_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411328","author":"NH Pedersen","year":"2023","unstructured":"Pedersen NH, S\u00f8rensen JA, Ghazanfar MN, Zhang DG, Vestergaard C, Thomsen SF (2023) Biomarkers for monitoring treatment response of omalizumab in patients with chronic urticaria. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241411328","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4591_CR17","doi-asserted-by":"publisher","first-page":"e20256169","DOI":"10.5826\/dpc.1504a6169","volume":"15","author":"ME G\u00fcner","year":"2025","unstructured":"G\u00fcner ME, \u00d6zt\u00fcrk P, Yaray OC, Evran K\u0131l\u0131\u00e7 EM, Ku\u015f MM (2025) Predictors of Early Response and Relapse in Chronic Spontaneous Urticaria Treated with Omalizumab: The Role of Age, Sex, Disease Duration, and UAS7. Dermatol Pract Concept 15(4):e20256169. https:\/\/doi.org\/10.5826\/dpc.1504a6169","journal-title":"Dermatol Pract Concept"},{"issue":"4","key":"4591_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40265-025-02170-4","volume":"85","author":"P Kolkhir","year":"2025","unstructured":"Kolkhir P, Fok JS, Kocat\u00fcrk E et al (2025) Update on the Treatment of Chronic Spontaneous Urticaria. Drugs 85(4):475\u2013486. https:\/\/doi.org\/10.1007\/s40265-025-02170-4","journal-title":"Drugs"},{"issue":"2","key":"4591_CR19","doi-asserted-by":"publisher","first-page":"AB239","DOI":"10.1016\/j.jaci.2019.12.135","volume":"145","author":"S Altrichter","year":"2020","unstructured":"Altrichter S, Staubach P, Pasha M et al (2020) Clinical activity of AK002, an anti-Siglec-8 monoclonal antibody, in treatment-refractory chronic urticaria. J Allergy Clin Immunol 145(2):AB239. https:\/\/doi.org\/10.1016\/j.jaci.2019.12.135","journal-title":"J Allergy Clin Immunol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04591-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-026-04591-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04591-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:02:56Z","timestamp":1788811376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-026-04591-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":19,"alternative-id":["4591"],"URL":"https:\/\/doi.org\/10.1007\/s11845-026-04591-w","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Clinical Research Ethics Committee of Inonu University Faculty of Medicine (decision no. 2019\/173). All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}}]}}